

---

**INFORMATION ONLY**

Vonvendi® - Interim Plasma Protein and Related Products Review Decision

Customer Letter # 2023-06

---

2023-03-20

Dear Colleagues:

Provincial and Territorial Ministries of Health have given approval to make Vonvendi eligible for listing on the condition of a lower price that demonstrates its value compared to plasma-derived products already on Canadian Blood Services' PPRP formulary.

This means Vonvendi will not be listed on the formulary at this time, and it will be eligible to be considered in the next appropriate Request for Proposal (RFP) in 3-5 years. Should Canadian Blood Services receive a proposal for Vonvendi from the manufacturer at the next appropriate RFP, Vonvendi could be eligible to be considered for treatment and control of bleeding episodes and perioperative management with criteria.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at [www.blood.ca](http://www.blood.ca) in the "Hospital Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier  
Director, Plasma Protein and Related Products Formulary Program